SANDOZ NEORAL TO REPLACE SANDIMMUNE AS ANTI-ORGAN REJECTION GOLD STANDARD, FIRM SAYS; CYCLOSPORINE MICROEMULSION COST WILL BE SAME AS SANDIMMUNE

Sandoz' Neoral microemulsion formulation of cyclosporine will surpass Sandimmune as the standard of therapy for organ transplant patients, Sandoz Transplant Business Sector General Manager Larry Bauer suggested in a July 19 teleconference announcing approval of the product.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Pink Sheet